Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119920 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
A Phase 2 study of Dry Eye Disease and Kerato Conjunctivitis Sicca, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
- 19
- Study locations
NCT05119920 is a Phase 2 study of Dry Eye Disease and Kerato Conjunctivitis Sicca that has completed, run by Glaukos Corporation. The registered enrollment target is 226 participants, roughly in line with the 248-participant average among 33 other Dry Eye Disease trials with a reported enrollment target. The trial reports 19 study locations across 12 states.
The verdict
NCT05119920, a Phase 2 study of Dry Eye Disease and Kerato Conjunctivitis Sicca, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye Disease.
Conditions Studied
Interventions
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 1
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 2
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 3
- DRUG Placebo Ophthalmic Topical Cream
Study Locations (19)
California
- Glaukos Investigator - Glendale
- Glaukos Investigator - Mission Hills
- Glaukos Investigator - Newport Beach
- Glaukos Investigator - Petaluma
- Glaukos Investigator - Rancho Cordova
Arizona
- Glaukos Investigator - Chandler
- Glaukos Investigator - Sun City
Tennessee
- Glaukos Investigator - Memphis
- Glaukos Investigator - Nashville
Texas
- Glaukos Investigator - Houston
- Glaukos Investigator - San Antonio
Colorado
- Glaukos Investigator - Grand Junction
Florida
- Glaukos Investigator - Fort Myers
Georgia
- Glaukos Investigator - Roswell
Missouri
- Glaukos Investigator - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2022-01-03 |
| Est. Completion | 2022-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05119920
The ClinicalTrials.gov registry entry for NCT05119920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 248-participant average among 33 other Dry Eye Disease trials with a reported enrollment target. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dry Eye Disease appearing as the primary indexed condition, and to 4 interventions - of which Pilocarpine Ophthalmic Topical Cream, Dose 1 is the first listed.
NCT05119920 reports 19 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05119920 about?
NCT05119920 is a clinical study titled "Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease". This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye Disease.
What is the current status of trial NCT05119920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2022-01-03. Estimated completion is 2022-07-27.
What conditions does trial NCT05119920 study?
This clinical trial studies the following conditions: Dry Eye Disease, Kerato Conjunctivitis Sicca.
What interventions are being tested in trial NCT05119920?
The interventions under investigation include: Pilocarpine Ophthalmic Topical Cream, Dose 1 (DRUG), Pilocarpine Ophthalmic Topical Cream, Dose 2 (DRUG), Pilocarpine Ophthalmic Topical Cream, Dose 3 (DRUG), Placebo Ophthalmic Topical Cream (DRUG).
Who is sponsoring clinical trial NCT05119920?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05119920 being conducted?
This trial has 19 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.